[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity
Shuttle Pharmaceuticals director Oleh Nabyt was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and is reported with a $0 price. The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027 and one-third on 08/08/2028. The award is reported as a direct beneficial holding and, if fully vested and converted, would result in receipt of up to 29,240 shares of common stock.
Al direttore di Shuttle Pharmaceuticals, Oleh Nabyt, sono state assegnate il 08/08/2025 29.240 unit脿 di azioni vincolate (RSU). Ciascuna RSU rappresenta il diritto condizionato a ricevere una azione ordinaria ed 猫 riportata con un prezzo di $0. Le RSU maturano in tre quote uguali: un terzo il 08/08/2026, un terzo il 08/08/2027 e un terzo il 08/08/2028. L'assegnazione 猫 indicata come una partecipazione diretta a beneficio e, se totalmente maturata e convertita, comporterebbe la ricezione fino a 29.240 azioni ordinarie.
Al director de Shuttle Pharmaceuticals, Oleh Nabyt, se le concedieron el 08/08/2025 29.240 unidades de acciones restringidas (RSU). Cada RSU otorga el derecho contingente a recibir una acci贸n ordinaria y figura con un precio de $0. Las RSU se consolidan en tres pagos iguales: un tercio el 08/08/2026, otro tercio el 08/08/2027 y el 煤ltimo tercio el 08/08/2028. La concesi贸n se reporta como una tenencia directa a beneficio y, si llegara a consolidarse y convertirse por completo, dar铆a lugar a la recepci贸n de hasta 29.240 acciones ordinarias.
Shuttle Pharmaceuticals鞚� 鞚挫偓 Oleh Nabyt鞐愱矊 2025雲� 8鞗� 8鞚�鞐� 29,240臧滌潣 鞝滍暅攵� 欤检嫕(RSU)鞚� 攵�鞐悩鞐堨姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 雮橅儉雮措┌, 臧�瓴╈潃 $0搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. RSU電� 3霌彪秳鞙茧 氩犾姢韺呺悩鞏� 2026雲� 8鞗� 8鞚�, 2027雲� 8鞗� 8鞚�, 2028雲� 8鞗� 8鞚�鞐� 臧侁皝 1/3鞌� 甓岆Μ臧� 頄夓偓霅╇媹雼�. 鞚� 氤挫儊鞚� 歆侅爲鞝侅澑 靾橃澋 氤挫湢搿� 氤搓碃霅橂┌, 氇憪 氩犾姢韸鸽悩瓿� 鞝勴櫂霅� 瓴届毎 斓滊寑 29,240欤�鞚� 氤错喌欤茧ゼ 靾橂牴頃橁矊 霅╇媹雼�.
Au directeur de Shuttle Pharmaceuticals, Oleh Nabyt, ont 茅t茅 attribu茅es le 08/08/2025 29 240 unit茅s d'actions restreintes (RSU). Chaque RSU conf猫re le droit conditionnel de recevoir une action ordinaire et est enregistr茅e avec un prix de $0. Les RSU sont soumises 脿 une acquisition en trois tranches 茅gales : un tiers le 08/08/2026, un tiers le 08/08/2027 et un tiers le 08/08/2028. L'attribution est d茅clar茅e comme une d茅tention directe 脿 titre b茅n茅ficiaire et, si elle 茅tait enti猫rement acquise et convertie, entra卯nerait la r茅ception de jusqu'脿 29 240 actions ordinaires.
Dem Direktor von Shuttle Pharmaceuticals, Oleh Nabyt, wurden am 08.08.2025 29.240 Restricted Stock Units (RSUs) gew盲hrt. Jede RSU berechtigt bedingt zum Erhalt einer Stammaktie und ist mit einem Preis von $0 angegeben. Die RSUs vesten in drei gleichen Raten: ein Drittel am 08.08.2026, ein Drittel am 08.08.2027 und ein Drittel am 08.08.2028. Die Zuwendung wird als direkte beg眉nstigte Beteiligung ausgewiesen und w眉rde bei vollst盲ndiger Vesting und Umwandlung zur Ausgabe von bis zu 29.240 Aktien der Stammaktien f眉hren.
- None.
- None.
Insights
TL;DR: Time鈥慴ased RSU grant to a director; appears routine and aimed at long鈥憈erm alignment rather than immediate cash compensation.
The grant of 29,240 RSUs to Director Oleh Nabyt is reported as a direct holding and vests in three equal annual tranches beginning one year after the grant date. As disclosed, each RSU converts to one share at a $0 price, indicating a typical equity鈥慴ased retention and alignment instrument. There is no indication in the filing of accelerated vesting conditions or performance metrics. From a governance perspective, this is a common board compensation practice and, based on the information provided, carries a neutral impact on shareholder governance dynamics.
TL;DR: Multi鈥憏ear vesting RSUs provide retention incentives; dilution impact depends on total outstanding shares (not disclosed here).
The award vests one鈥憈hird annually on 08/08/2026, 08/08/2027 and 08/08/2028, creating retention incentives through 2028. The filing specifies that each RSU equals one share if and when settled. The reported $0 price is standard for restricted stock units. The filing does not state the company's total shares outstanding or the proportionate dilution from this grant, so materiality to shareholders cannot be quantified from the provided content.
Al direttore di Shuttle Pharmaceuticals, Oleh Nabyt, sono state assegnate il 08/08/2025 29.240 unit脿 di azioni vincolate (RSU). Ciascuna RSU rappresenta il diritto condizionato a ricevere una azione ordinaria ed 猫 riportata con un prezzo di $0. Le RSU maturano in tre quote uguali: un terzo il 08/08/2026, un terzo il 08/08/2027 e un terzo il 08/08/2028. L'assegnazione 猫 indicata come una partecipazione diretta a beneficio e, se totalmente maturata e convertita, comporterebbe la ricezione fino a 29.240 azioni ordinarie.
Al director de Shuttle Pharmaceuticals, Oleh Nabyt, se le concedieron el 08/08/2025 29.240 unidades de acciones restringidas (RSU). Cada RSU otorga el derecho contingente a recibir una acci贸n ordinaria y figura con un precio de $0. Las RSU se consolidan en tres pagos iguales: un tercio el 08/08/2026, otro tercio el 08/08/2027 y el 煤ltimo tercio el 08/08/2028. La concesi贸n se reporta como una tenencia directa a beneficio y, si llegara a consolidarse y convertirse por completo, dar铆a lugar a la recepci贸n de hasta 29.240 acciones ordinarias.
Shuttle Pharmaceuticals鞚� 鞚挫偓 Oleh Nabyt鞐愱矊 2025雲� 8鞗� 8鞚�鞐� 29,240臧滌潣 鞝滍暅攵� 欤检嫕(RSU)鞚� 攵�鞐悩鞐堨姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 雮橅儉雮措┌, 臧�瓴╈潃 $0搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. RSU電� 3霌彪秳鞙茧 氩犾姢韺呺悩鞏� 2026雲� 8鞗� 8鞚�, 2027雲� 8鞗� 8鞚�, 2028雲� 8鞗� 8鞚�鞐� 臧侁皝 1/3鞌� 甓岆Μ臧� 頄夓偓霅╇媹雼�. 鞚� 氤挫儊鞚� 歆侅爲鞝侅澑 靾橃澋 氤挫湢搿� 氤搓碃霅橂┌, 氇憪 氩犾姢韸鸽悩瓿� 鞝勴櫂霅� 瓴届毎 斓滊寑 29,240欤�鞚� 氤错喌欤茧ゼ 靾橂牴頃橁矊 霅╇媹雼�.
Au directeur de Shuttle Pharmaceuticals, Oleh Nabyt, ont 茅t茅 attribu茅es le 08/08/2025 29 240 unit茅s d'actions restreintes (RSU). Chaque RSU conf猫re le droit conditionnel de recevoir une action ordinaire et est enregistr茅e avec un prix de $0. Les RSU sont soumises 脿 une acquisition en trois tranches 茅gales : un tiers le 08/08/2026, un tiers le 08/08/2027 et un tiers le 08/08/2028. L'attribution est d茅clar茅e comme une d茅tention directe 脿 titre b茅n茅ficiaire et, si elle 茅tait enti猫rement acquise et convertie, entra卯nerait la r茅ception de jusqu'脿 29 240 actions ordinaires.
Dem Direktor von Shuttle Pharmaceuticals, Oleh Nabyt, wurden am 08.08.2025 29.240 Restricted Stock Units (RSUs) gew盲hrt. Jede RSU berechtigt bedingt zum Erhalt einer Stammaktie und ist mit einem Preis von $0 angegeben. Die RSUs vesten in drei gleichen Raten: ein Drittel am 08.08.2026, ein Drittel am 08.08.2027 und ein Drittel am 08.08.2028. Die Zuwendung wird als direkte beg眉nstigte Beteiligung ausgewiesen und w眉rde bei vollst盲ndiger Vesting und Umwandlung zur Ausgabe von bis zu 29.240 Aktien der Stammaktien f眉hren.
FAQ
What did Shuttle Pharmaceuticals (SHPH) report for insider activity?
What does each RSU represent in the SHPH Form 4?
When do the RSUs granted to Nabyt vest?
Was there a purchase price for the RSUs in the SHPH grant?
Is the reported ownership direct or indirect?
